| 0.204 -0.043 (-17.54%) | 03-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.32 |
1-year : | 0.43 |
| Resists | First : | 0.27 |
Second : | 0.37 |
| Pivot price | 0.18 |
|||
| Supports | First : | 0.12 | Second : | 0.1 |
| MAs | MA(5) : | 0.21  |
MA(20) : | 0.18 |
| MA(100) : | 0.58 |
MA(250) : | 0.49 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 79.9 |
D(3) : | 79.8 |
| RSI | RSI(14): 42.6 |
|||
| 52-week | High : | 1.42 | Low : | 0.12 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BCAB ] has closed below upper band by 33.9%. Bollinger Bands are 66.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.21 - 0.21 | 0.21 - 0.21 |
| Low: | 0.17 - 0.17 | 0.17 - 0.17 |
| Close: | 0.2 - 0.2 | 0.2 - 0.21 |
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Mon, 02 Mar 2026
BioAtla (BCAB) CFO sees 1,802 shares withheld for RSU tax settlement - Stock Titan
Mon, 02 Mar 2026
[Form 4] BioAtla, Inc. Insider Trading Activity - Stock Titan
Mon, 02 Mar 2026
BioAtla (BCAB) CMO reports 3,140-share tax withholding on RSU vesting - Stock Titan
Mon, 02 Mar 2026
BioAtla, Inc. Initiates Strategic Review Process and Workforce Restructuring to Enhance Shareholder Value - Quiver Quantitative
Mon, 02 Mar 2026
Biotech BioAtla to shed 70% of staff while weighing asset sales - Stock Titan
Sun, 01 Mar 2026
BCAB PE Ratio & Valuation, Is BCAB Overvalued - Intellectia AI
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 74 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 5.3 (%) |
| Held by Institutions | 22.5 (%) |
| Shares Short | 6,610 (K) |
| Shares Short P.Month | 4,320 (K) |
| EPS | -1.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.53 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -105.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.63 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.88 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -57 (M) |
| Levered Free Cash Flow | -33 (M) |
| PE Ratio | -0.18 |
| PEG Ratio | 0 |
| Price to Book value | -0.39 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.27 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|